1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S1-S45.
2. Lowes R. Top 100 selling drugs through September reported. Medscape Med News. WebMD, LLC. 2013. Medscape Web site. Available at: http://www.medscape.com/viewarticle/813571#3 . Accessed December 11, 2013.
3. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med . 2013;158:526-534.
4. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246,955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes . 2013;6:390-399.
5. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106:1024-1028.
6. Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab . 2010;95:2015-2022.
7. Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev . 2012;40:188-194.
8. Mansi I, Frei CR, Pugh MJ, et al. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med . 2013;173: 1-10.
9. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther . 2005;19: 403-414.
10. Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78:393-403.
11. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol . 2006;97:52C-60C.
12. Elsevier/Gold Standard. Gold Standard Drug Database. Elsevier/Gold Standard Web site. Available at: http://www.goldstandard.com/product/gold-standard-drug-database/ . Accessed December 4, 2013.
13. US Food and Drug Administration. FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. US Food and Drug Administration Web site. Available at: http://www.fda.gov/drugs/drugsafety/ucm293101.htm . Accessed July 23, 2014.
14. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation . 2006;114:2788-2797.
15. US Food and Drug Administration. FDA drug safety communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. US Food and Drug Administration Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882.htm . Updated February 15, 2012. Accessed December 9, 2013.
16. Bowman L, Armitage J, Bulbulia R, et al; SEARCH Study Collaborative Group. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am J Heart . 2007;154:815-823.
17. Mills EJ, O’Regan C, Eyawo O, et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40,000 patients. Euro Heart J . 2011;32:1409-1415.
18. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol . 2012;110:526-529.
19. Parker BA, Gregory SM, Lorson L, et al. A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design. J Clin Lipidol . 2013;7:187-193.
20. Fedacko J, Pella D, Fedackova P, et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. Can J Physiol Pharmacol . 2013;91:165-170.
21. Jellin JM, Gregory PJ, et al. Natural Medicines Comprehensive Database. University of Wyoming Libraries Web site. Available at: http://www.naturaldatabase.com.libproxy.uwyo.edu . Accessed December 4, 2013.
22. de Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy . 2004;24:584-591.
23. Lewis JH. Clinical perspective: statins and the liver—harmful or helpful? Dig Dis Sci . 2012;57:1754-1763.
24. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol . 2013;111:1123-1130.
25. Agarwal R. Effects of statins on renal function. Am J Cardiol . 2006;97:748-755.
26. Fried LF, Orchard TJ, Lasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int . 2001;59:260-269.
27. Fellström B, Holdaas H, Jardine AG, et al; Assessment of Lescol in Renal Transportation Study Investigators. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) Trial. Kidney Int . 2004;66:1549-1555.
28. McKenney JM, Davidson MH, Jacobson TA, et al; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol . 2006;97:89C-94C.
29. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int. 2013;3(suppl):S259-S305.
30. Goldstein LB, Amarenco P, Szarek M, et al; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology . 2008;70(24 pt 2):2364-2370.
31. Goldstein LB, Amarenco P, Lamonte M, et al; SPARCL investigators. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke . 2008;39:2444-2448.
32. Westover MB, Bianchi MT, Eckman MH, et al. Statin use following intracerebral hemorrhage: a decision analysis. Arch Neurol . 2011;68:573-579.
33. Biffi A, Devan WJ, Anderson CD, et al. Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. Neurology . 2011;76:1581-1588.
34. Dowlatshahi D, Demchuck AM, Fang J, et al; Registry of the Canadian Stroke Network. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. Stroke . 2012;43:1518-1523.
35. Bustamante A, Montaner J. Statin therapy should not be discontinued in patients with intracerebral hemorrhage. Stroke . 2013;44:2060-2061.
36. Morgenstern LB, Hemphill JC 3rd, Anderson C, et al; American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke . 2010;41:2108-2129.
37. Shepherd J, Blauw GJ, Murphy MB, et al; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
38. Jukema JW, Cannon CP, de Craen AJ, et al. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol . 2012;60:875-881.
39. Alberton M, Wu P, Druyts E, et al. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM . 2012;105:145-157.
40. Baigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
41. Emberson JR, Kearney PM, Blackwell L, et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7:e29849.
42. Klein BE, Klein R, Lee KE, et al. Statin use and incident nuclear cataract. JAMA. 2006;295:2752-2758.
43. Fong DS, Poon KY. Recent statin use and cataract surgery. Am J Ophthalmol . 2012;153:222-228.e1.
44. Chodick G, Heymann AD, Flash S, et al. Persistence with statins and incident cataract: a population-based historical cohort study. Ann Epidemiol. 2010;20:136-142.
45. Tan JS, Mitchell P, Rochtchina E, et al. Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. Am J Ophthalmol . 2007;143:687-689.
46. Machan CM, Hrynchak PK, Irving EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci . 2012;89:1165-1171.
47. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ . 2010;340:c2197.
48. Leuschen J, Mortensen EM, Frei CR, et al. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol . 2013;131:1427-1434.
49. Fraunfelder FW, Richards AB. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Ophthalmology . 2008;115:2282-2285.
50. AHFS Drug Information 2013. Bethesda, MD: American Society of Health-System Pharmacists; 2013.
51. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(suppl 5): S213-S256.
52. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:410-414.
